CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

A linear dose-dependent analysis showed that each daily consumption of 12 g of alcohol increased the risks for cirrhosis and hepatocellular carcinoma by 6.2% and 11.5%, respectively. HealthDay News — ...

Her expertise is in personal finance and investing, and real estate. Real gross domestic product (GDP) is an inflation-adjusted measure that reflects the value of all goods and services produced ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...

HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver ...